Huntington’s Disease
Huntington’s disease, also known as Huntington’s chorea, is a hereditary neurodegenerative disorder that affects both the brain and the body. It is named after Dr. George Huntington, who first described the condition in the late 19th century.
Huntington’s disease is caused by a genetic mutation in the huntingtin gene (HTT), which leads to the production of abnormal huntingtin protein. The mutation involves an abnormal repetition of the CAG trinucleotide within the gene, causing an expansion of the repeating sequence. The more repeats a person has, the earlier and more severe the onset of the disease tends to be.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Huntington’s Disease.
-
Publication date: Jul 07, 2026 Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder ...
-
Cortistatin as a modulator of inflammatory and mitochondrial dysfunction in Huntington´s disease.
Publication date: Jul 07, 2026 Huntington’s disease (HD) is an inherited, fatal neurodegenerative disorder caused ... -
Kynurenic Acid, a Key Endogenous Neuroprotective Agent: Role of Its Derivatives in Therapeutics.
Publication date: Jul 07, 2026 Kynurenic acid (KYNA) is an endogenous molecule that acts as ... -
The experiences of partners of individuals with pre-symptomatic Huntington’s disease: a reflexive thematic analysis.
Publication date: Jul 08, 2026 Individuals with the Huntington disease gene can often remain symptom ... -
Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
Publication date: Jul 08, 2026 Ferrer and Prilenia have initiated the confirmatory PRECISEHD study, a ... -
New Platform Combines Precision Gene Targeting with Brain-Wide Delivery
Publication date: Jul 09, 2026 The team then screened the vectors in mice whose brains ... -
CDKN1A protects medium spiny neurons from Huntington’s disease pathology.
Publication date: Jul 06, 2026 Huntington’s disease (HD) arises from abnormal expansion of CAG trinucleotide ... -
Structural insights into the MLH1-FAN1 interaction reveal an uncharacterized binding interface on MLH1.
Publication date: Jul 06, 2026 Huntington’s disease is driven by CAG repeat expansion in the ... -
Beyond the gene: Targeting neuroinflammation in Huntington’s disease
Publication date: Jul 06, 2026 Dr. Sarah Camargos is joined by Dr. Rajeev Kumar to ... -
Novel Compounds for Treating Huntington’s Disease.
Publication date: Apr 09, 2026 Provided herein are novel compounds, pharmaceutical compositions, use of such ... -
Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases.
Publication date: Apr 14, 2026 Background: Neurodegenerative diseases are a major health problem, and the ... -
Keap1-Nrf2 Signaling Pathway-Mediated Antioxidant Defense in Neurodegenerative Diseases: Mechanisms and Traditional Chinese Medicine Therapeutic Strategies.
Publication date: Apr 17, 2026 Neurodegenerative diseases (NDs) are incurable, progressively disabling disorders marked by ... -
Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation.
Publication date: Apr 14, 2026 The sigma-1 receptor (S1R) is an endoplasmic reticulum (ER)-resident protein ... -
The Dual Role of Connexins in Stroke, Neurotrauma, Neurodegenerative and Psychiatric Disorders: A Global Systematic Review.
Publication date: Apr 19, 2026 Background: Connexins (Cx) are a family of transmembrane proteins that ... -
Sequential Clinical Changes Following Autologous Mesenchymal Stem Cell Therapy in a Patient With Concurrent Huntington’s Disease and Ankylosing Spondylitis: A Case Report.
Publication date: May 01, 2026 Huntington’s disease (HD) and ankylosing spondylitis (AS) are genetically and ... -
Gene Editing Strategies for Neurological and Mental Disorders: Advances in Delivery, Methodology, and Clinical Translation.
Publication date: Apr 19, 2026 Neurological and mental disorders are among the main causes of ... -
Population-scale repeat expansions elucidate disease risk and brain atrophy.
Publication date: May 01, 2026 Pathogenic expansions of short tandem repeats (STRs) cause over 70 ... -
Phosphodiesterase 9 (PDE9) Inhibitors May Provide Effective Treatments for Neurodegenerative, Cardiovascular and Other Diseases.
Publication date: May 14, 2026 The invention in this patent application relates to 4-oxo-4,5-dihydro-1H-pyrazolo--pyrimidine-3-carbonitrile derivatives ... -
Odd-Chain Fatty Acids-Enriched Algal Oil Improves Locomotor Function and Modulates Metabolic Pathways in Caenorhabditis elegans Model of Alzheimer’s Disease.
Publication date: May 19, 2026 Alzheimer’s disease (AD) is a common age-related neurodegenerative disorder with ... -
Cosolutes Modulate Polyubiquitin Fibrillation.
Publication date: May 19, 2026 Ubiquitin, a 76-residue polypeptide, functions as a post-translational modifier and ... -
Short CAG repeat variation as a regulatory factor in health and disease.
Publication date: May 19, 2026 Short cytosine-adenine-guanine (CAG) trinucleotide repeats, which encode polyglutamine (polyQ) tracts, ...